China Medicine Corporation's Levocarnitine Dried Powder Injection Was Registered with the Ministry of Health of Pakistan

China Medicine Corporation's Levocarnitine Dried Powder Injection Was
Registered with the Ministry of Health of Pakistan

GUANGZHOU, China, Oct. 20 /PRNewswire-Asia/ -- China Medicine Corporation
(OTC Bulletin Board: CHME) ("China Medicine" or "the Company"), a leading
distributor and developer of prescription and over-the-counter
pharmaceuticals,
traditional Chinese medicines ("TCM"), nutritional and dietary-supplements,
medical devices, and medical formulations in the People's Republic of China
("PRC"), announced today that one of its major products distributed by its
fully owned subsidiary, Guangzhou Konzern Pharmaceutical Co., Ltd. ("Guangzhou
Konzern"), Levocarnitine Dried Powder Injection ("Levocarnitine"), was
registered with the Ministry of Health of Pakistan on September 25, 2009. The
registration number of Levocarnitine in Pakistan is 059054.
Guangzhou Konzern entered into a two-year Distribution and Supply
Agreement of Levocarnitine ("Agreement") with RG Pharmaceutica (Pvt.) Ltd.
("RGP"), a Pakistani pharmaceutical distributor. The agreement stipulates that
RGP will be responsible for the product registration, importation and
marketing within the territory of Pakistan. Levocarnitine is used to treat
coronary heart disease and acute myocardial infarction. Currently, there are
no pharmaceutical products similar to Levocarnitine in Pakistan, and the
potential market for Levocarnitine in Pakistan is estimated at 2 million vials
per year.
China Medicine expects to launch Levocarnitine in Pakistan in January 2010.
The Company expects to ship approximately 100,000 vials of Levocarnitine
within the first year of entering the market in Pakistan and estimates that
gross margin for the product will not be less than 65%. Levocarnitine is
manufactured by Guangzhou Lifetech Pharmaceutical Co., Ltd. in China
("Lifetech"). Lifetech is Guangzhou Konzern's exclusive Original Equipment
Manufacturer ("OEM"). Guangzhou Konzern distributed Levocarnitine in China in
the years of 2008 and 2007, which generated revenues of $1,470,333 and
$1,253,185 and gross profits of $570,074 and $473,006.
"We are excited to be able to export our OEM manufactured Levocarnitine
powder injection to Pakistan, marking a major milestone for our company in
entering this overseas pharmaceutical market," commented Mr. Senshan Yang,
Chairman and CEO of China Medicine. "In addition, we believe our strategic
move to tap into the international pharmaceutical market overall will increase
our profitability and maximize shareholder value."
About China Medicine Corporation
China Medicine Corporation is a leading pharmaceutical company that
researches and develops medical formulations and distributes over 2,200
pharmaceutical products in China including prescription and over the counter
("OTC") drugs, traditional Chinese medicine products, herbs and
dietary-supplements. The Company distributes its products to more than 300
hospitals, 500 medicine companies, and 1,788 drug stores through wholesale
distributors in 28 provinces throughout China. The Company actively develops a
number of proprietary products for a variety of uses, including oncology, high
blood pressure and the removal of toxins from food and animal feeds. For more
information visit the Company's website at http://www.chinamedicinecorp.com .
Cautionary Statement
This press release contains forward-looking statements concerning the
Company's business and products. The Company's actual results may differ
materially depending on a number of risk factors including, but not limited
to,
the following: general economic and business conditions, obtaining regulatory
approval for new products, the expected contribution of higher margin
products,
government support for rural health care, competition from existing and new
competitors, changes in technology, and various other factors beyond its
control. All forward-looking statements are expressly qualified in their
entirety by this Cautionary Statement and the risk factors detailed in the
Company's reports filed with the Securities and Exchange Commission. China
Medicine Corporation undertakes no duty to revise or update any
forward-looking statements to reflect events or circumstances after the date
of this release.
For more information, please contact:

Company Contact:
Mr. Richard Wu
Chief Financial Officer
China Medicine Corporation
Tel: +86-20-8737-2231
Email: richardpdwu@gmail.com

Investor Relations Contact:
Mr. Crocker Coulson, President
CCG Investor Relations
Tel: +1-646-213-1915 (NY Office)
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com

SOURCE China Medicine Corporation

Company Contact: Mr. Richard Wu, Chief Financial Officer, China Medicine
Corporation, +86-20-8737-2231, richardpdwu@gmail.com; Investor Relations
Contact: Mr. Crocker Coulson, President, CCG Investor Relations,
+1-646-213-1915 (NY Office), crocker.coulson@ccgir.com